GlaxoSmithKline ($GSK) is touting stellar Phase III results for an in-development combo therapy for melanoma, saying its treatment beat out Roche's ($RHHBY) Zelboraf in overall survival and led independent advisers to recommend an early end for the study. GSK is testing a combination of the MEK inhibitor trametinib (approved as Mekinist) and the BRAF-blocking dabrafenib (Tafinlar) against Roche's drug in patients with cutaneous melanoma and mutations in their BRAF genes. In an interim analysis, the combo's overall survival benefit compared to Zelboraf crossed the prespecified stopping point, GSK said, and its independent data monitoring committee has recommended that the trial end early. More